Dyskinesia - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 147
Inquire Before Buying

Dyskinesia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Dyskinesia - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia - Overview 8
Dyskinesia - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Dyskinesia - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Dyskinesia - Companies Involved in Therapeutics Development 28
Adamas Pharmaceuticals Inc 28
Addex Therapeutics Ltd 28
Advicenne SA 29
Avanir Pharmaceuticals Inc 29
Bionomics Ltd 29
Catalyst Biosciences Inc 30
Cavion LLC 30
Clevexel Pharma SAS 31
EpiVax Inc 31
Heptares Therapeutics Ltd 31
Ipsen SA 32
Merz Pharma GmbH & Co KgaA 32
Neurim Pharmaceuticals Ltd 33
Neurocrine Biosciences Inc 33
Neurolixis Inc 33
Osmotica Pharmaceutical Corp 34
Phenomenome Discoveries Inc 34
Sage Therapeutics Inc 35
SciFluor Life Sciences LLC 35
SOM Biotech SL 35
Synchroneuron Inc 36
Dyskinesia - Drug Profiles 37
(dextromethorphan + quinidine sulfate) - Drug Profile 37
A-2M13677 - Drug Profile 42
abobotulinumtoxinA - Drug Profile 43
acamprosate calcium SR - Drug Profile 47
amantadine hydrochloride ER - Drug Profile 49
amantadine hydrochloride ER - Drug Profile 59
AT-127 - Drug Profile 60
AT-326 - Drug Profile 61
AT-403 - Drug Profile 62
befiradol - Drug Profile 63
brexanolone - Drug Profile 65
CVXL-0107 - Drug Profile 74
CX-8998 - Drug Profile 75
cycloserine - Drug Profile 76
dipraglurant IR - Drug Profile 77
Drug for Dyskinesia - Drug Profile 82
Drug for Tardive Dyskinesia - Drug Profile 83
Drugs for Dyskinesia - Drug Profile 84
Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile 85
HTL-14242 - Drug Profile 86
incobotulinumtoxin A - Drug Profile 87
IRL-790 - Drug Profile 92
JM-010 - Drug Profile 93
MLR-1019 - Drug Profile 95
NBI-640756 - Drug Profile 96
Neu-120 - Drug Profile 97
Neu-240 - Drug Profile 98
onabotulinumtoxinA - Drug Profile 99
PCT-3010 - Drug Profile 100
PPI-1011 - Drug Profile 101
RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile 102
SAGE-217 - Drug Profile 103
SK-609 - Drug Profile 107
Small Molecule for Dyskinesia - Drug Profile 108
Small Molecule for Dyskinesia - Drug Profile 109
Small Molecules for Neurodegenerative Disease - Drug Profile 110
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 111
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 112
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 113
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 114
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 115
SOM-3355 - Drug Profile 116
TC-8831 - Drug Profile 117
tetrabenazine - Drug Profile 118
valbenazine tosylate - Drug Profile 119
Dyskinesia - Dormant Projects 127
Dyskinesia - Discontinued Products 129
Dyskinesia - Product Development Milestones 130
Featured News & Press Releases 130
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 143
Disclaimer 144

List of Tables
Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Advicenne SA, H2 2017
Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Bionomics Ltd, H2 2017
Dyskinesia - Pipeline by Catalyst Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Cavion LLC, H2 2017
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2017
Dyskinesia - Pipeline by EpiVax Inc, H2 2017
Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Ipsen SA, H2 2017
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Neurolixis Inc, H2 2017
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H2 2017
Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2017
Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2017
Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H2 2017
Dyskinesia - Pipeline by SOM Biotech SL, H2 2017
Dyskinesia - Pipeline by Synchroneuron Inc, H2 2017
Dyskinesia - Dormant Projects, H2 2017
Dyskinesia - Dormant Projects, H2 2017 (Contd..1), H2 2017
Dyskinesia - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • United States Gabapentin Market 2018 by Manufacturers, States, Type and Application, Forecast to 2023
    Published: 04-Jun-2018        Price: US 4480 Onwards        Pages: 104
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. Scope of the Report: This report focuses on the Gabapentin in United States market, to split the market based on manufacturers, ......
  • United States Gabapentin Market Report 2018
    Published: 30-May-2018        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Gabapentin market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Gabap......
  • United States Alcohol Addiction Therapeutics Market Report 2018
    Published: 28-May-2018        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Alcohol Addiction Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and ......
  • Global Gabapentin Market Research Report 2018
    Published: 24-May-2018        Price: US 2900 Onwards        Pages: 110
    In this report, the global Gabapentin market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gabapentin in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - China - Japan ......
  • Global Gabapentin Sales Market Report 2018
    Published: 24-May-2018        Price: US 4000 Onwards        Pages: 113
    In this report, the global Gabapentin market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Gabapentin for these regions, from 2013 to 2025 (forecast), covering - United States - China - Europe - Japan - South......
  • Global Alcohol Addiction Therapeutics Market Research Report 2018
    Published: 22-May-2018        Price: US 2900 Onwards        Pages: 117
    This report studies the global Alcohol Addiction Therapeutics market status and forecast, categorizes the global Alcohol Addiction Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. In 2017, the global Alcohol Addiction Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, ......
  • Global Alcohol Addiction Therapeutics Sales Market Report 2018
    Published: 22-May-2018        Price: US 4000 Onwards        Pages: 114
    This report studies the global Alcohol Addiction Therapeutics market status and forecast, categorizes the global Alcohol Addiction Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). In 2017, the global Alcohol Addiction Therapeutics market size was xx million US$ and it is expect......
  • Global Gabapentin Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 09-May-2018        Price: US 3480 Onwards        Pages: 104
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. Scope of the Report: This report focuses on the Gabapentin in global market, especially in North America, Europe, Asia-P......
  • Global and United States Gabapentin Market Research by Company, Type & Application 2013-2025
    Published: 28-Apr-2018        Price: US 2000 Onwards        Pages: 95
    Summary Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. Market Segment as follows: By Type - Tablet - Capsule By Application - Nerve Pain - Restless Legs Syndrome - Seizures By Company - Pfizer - GSK - Sailike - Jiangsu Enhua......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs